• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kairos Pharma, Ltd. Common Stock (NY:KAPA)

    0.7999 -0.0104 (-1.28%)
    Delayed Quote Updated: 12:10 PM EDT, Oct 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Kairos Pharma, Ltd. Common Stock

    < Previous 1 2 3 Next >
    BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV-105 in Prostate Cancer
    Via Investor Brand Network
    News headline image
    Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
    From Kairos Pharma, Ltd
    Via Business Wire
    NetworkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present KROS-101 Research at Discovery on Target Conference
    Via Investor Brand Network
    News headline image
    Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
    From Kairos Pharma, Ltd
    Via Business Wire
    InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) CEO to Present at H.C. Wainwright 28th Annual Global Investment Conference
    Via Investor Brand Network
    News headline image
    Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
    From Kairos Pharma, Ltd
    Via Business Wire
    News headline image
    Kairos Pharma Announces 1-for-7 Reverse Stock Split
    From Kairos Pharma, Ltd
    Via Business Wire
    TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Collaborates With Bayer to Evaluate Combination Therapy for Advanced Prostate Cancer
    Via Investor Brand Network
    News headline image
    Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
    From Kairos Pharma, Ltd
    Via Business Wire
    BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Favorable Interim Phase 1 Safety Data for ENV-105 in EGFR-Mutated Lung Cancer
    Via Investor Brand Network
    News headline image
    Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
    From Kairos Pharma, Ltd
    Via Business Wire
    TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Pipeline Expansion and Clinical Milestones in Mid-Year Shareholder Update
    Via Investor Brand Network
    News headline image
    Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
    From Kairos Pharma, Ltd
    Via Business Wire
    BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives 2026 Healthcare Innovation Award for Drug Resistance Research
    Via Investor Brand Network
    News headline image
    Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
    From Kairos Pharma, Ltd
    Via Business Wire
    InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at LD Micro Invitational XVI
    Via Investor Brand Network
    TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Sets Virtual Annual Meeting, Discloses Going Concern Notice
    Via Investor Brand Network
    Topics Regulatory Compliance
    News headline image
    Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
    From Kairos Pharma, Ltd
    Via Business Wire
    InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Earns 2026 Pinnacle Award for Biotech Innovation in Cancer Drug Resistance
    Via Investor Brand Network
    News headline image
    Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
    From Kairos Pharma, Ltd
    Via Business Wire
    News headline image
    Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
    From Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
    From The Rosen Law Firm, P.A.
    Via Business Wire
    BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Enters Binding Terms To Acquire CL-273 For EGFR-Mutant Lung Cancer
    Via Investor Brand Network
    News headline image
    Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
    From Kairos Pharma, Ltd
    Via Business Wire
    BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets
    Via Investor Brand Network
    News headline image
    Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
    From Kairos Pharma, Ltd
    Via Business Wire
    TinyGemsBreaks – To Participate In DealFlow Discovery Conference
    Via Investor Brand Network
    News headline image
    Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
    From Kairos Pharma, Ltd
    Via Business Wire
    InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives Clinical Trials Arena Research and Development Award for Advanced Prostate Cancer
    Via Investor Brand Network
    News headline image
    Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
    From Kairos Pharma, Ltd
    Via Business Wire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.